Skip to main content
Clinical Trials/NCT05314309
NCT05314309
Active, not recruiting
Not Applicable

Clinical Validation of a Multi-target Faecal Immunochemical Test (mtFIT) Versus a Faecal Immunochemical Test (FIT) for Detecting Advanced Neoplasia in Population Screening for CRC: a Prospective Cohort Study With Paired Design

The Netherlands Cancer Institute1 site in 1 country14,712 target enrollmentMarch 25, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
CRC
Sponsor
The Netherlands Cancer Institute
Enrollment
14712
Locations
1
Primary Endpoint
Detection rate of advanced neoplasia
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

The primary goal of the population-based colorectal (CRC) screening is early detection and interception of CRC and its precursors to decrease CRC-related morbidity and mortality. To improve current CRC screening programs, the investigators have developed and retrospectively validated a test that combines the detection of multiple proteins in stool (the multitarget faecal immunochemical test, mtFIT). mtFIT was found to have a higher accuracy to detect advanced neoplasia (AN), which includes CRC, advanced adenomas and advanced serrated polyps, in comparison to FIT. Thus, this multitarget test has the potential to improve the screening program's efficiency in reducing CRC-related incidence, morbidity and mortality. This new test, in comparison to FIT, shows specifically higher sensitivity in the detection of advanced adenomas, without affecting specificity.

Detailed Description

Background: The primary goal of population-based CRC screening is early detection and interception of CRC and its precursors to decrease CRC-related morbidity and mortality. New tests, with higher sensitivity for advanced precursor lesions than the current FIT, are desired. The investigators have developed a protein-based multitarget faecal immunochemical test (mtFIT) that shows higher sensitivity for advanced adenomas without losing in specificity. Objective: To prospectively validate the better performance of the mtFIT in comparison to FIT in the setting of a population-based CRC screening program. Material and Methods: In this prospective study, participants of the Dutch National CRC screening program (55-75 years of age) will be invited to participate. Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings. Expected results: mtFIT has higher sensitivity for AN, and in particular advanced adenomas, than FIT, at equal positivity rate.

Registry
clinicaltrials.gov
Start Date
March 25, 2022
End Date
May 31, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Individuals of the Dutch population suitable for CRC screening (age between 55 and 75 years old) will be randomly selected.
  • The participants will be invited in phases and are selected out of different age groups.
  • The selected participants will participate in the population CRC screening program for either the first, second, third or fourth time.

Exclusion Criteria

  • Collection of stool not complete for both tests (FIT and mtFIT)

Outcomes

Primary Outcomes

Detection rate of advanced neoplasia

Time Frame: 10 months

Relative sensitivity of mtFIT compared to FIT in the detection of advanced neoplasia (AN; CRC, advanced adenomas and advanced serrated polyps) at an equal positivity rate.

Secondary Outcomes

  • Diagnostic yield of mtFIT in comparison to FIT(10 months)

Study Sites (1)

Loading locations...

Similar Trials